S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:ONVOOrganovo Stock Price, Forecast & News

$0.64
+0.06 (+10.26 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.59
Now: $0.64
$0.68
50-Day Range
$0.48
MA: $0.60
$0.74
52-Week Range
$0.19
Now: $0.64
$0.93
Volume1.37 million shs
Average Volume1.08 million shs
Market Capitalization$84.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Read More
Organovo logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.20 million
Book Value$0.20 per share

Profitability

Net Income$-18,710,000.00
Net Margins-798.68%

Miscellaneous

Employees70
Market Cap$84.20 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

Organovo (NASDAQ:ONVO) Frequently Asked Questions

How has Organovo's stock been impacted by COVID-19 (Coronavirus)?

Organovo's stock was trading at $0.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 148.0% and is now trading at $0.6449. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Organovo.

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) released its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analysts' expectations of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 60.96%. View Organovo's earnings history.

Has Organovo been receiving favorable news coverage?

News articles about ONVO stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Organovo earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the immediate future. View the latest news about Organovo.

Are investors shorting Organovo?

Organovo saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,320,000 shares, a drop of 16.5% from the June 15th total of 1,580,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is currently 0.9 days. Approximately 1.0% of the company's stock are short sold. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

Who are Organovo's key executives?

Organovo's management team includes the following people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.64.

How big of a company is Organovo?

Organovo has a market capitalization of $84.20 million and generates $2.20 million in revenue each year. Organovo employs 70 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.